A critical assessment of Even Healthcare’s Khosla-led Series B — a Bengaluru managed-care startup abandoning insurance to build its own hospitals, two months after laying off a third of its staff. The announced round, valuation, and total-raised figures all run ahead of what the company’s regulatory filings show.
The announced $50M, the ~$300M valuation, and the “>$120M total raised” all sit above what independent trackers and RoC filings show — a ~₹208 Cr (~$22M) Series B and $72.5M–$90M total. The headline figure may bundle an earlier ~$20M round or be aspirational. Diligence should run off filings, not the press release.
Even launched as explicitly not insurance, expanded into retail insurance distribution, and is now winding that down to become an asset-heavy hospital operator — its third model in five years. A 30–35% layoff accompanied the shift. “Doubling down” is the headline; strategic churn is the substance.
The thesis rests on a sub-1% readmission rate and 40% shorter stays. Every one of those numbers traces back to Even itself — no third-party clinical audit, no peer-reviewed data, on a young, self-selected Bengaluru membership base that isn’t comparable to population hospital statistics.
Key Finding: Even is attacking a genuine problem — India’s fee-for-service hospitals profit from doing more, not from making patients well. But the company is funding that fight by abandoning an asset-light model for 20-year hospital leases while losing roughly 3× its revenue, and it has never publicly explained how it finances five more hospitals or when corporate (not unit) profitability arrives. The gap between the announced round and the filed round is the first thing any serious buyer should reconcile.
The TechCrunch framing — an investor adding conviction to a winning model — obscures a company that has now reversed its own strategy twice. Each pivot was real; the question is whether the latest one is a thesis or a last resort.
Launched explicitly as not insurance: preventive and primary care delivered across 100+ partner hospitals. Asset-light.
Expanded into retail health-insurance distribution with cashless cover and policy portability — the opposite of the original pitch.
Now winding down insurance to build and operate its own multispecialty hospitals on 20-year leases. Asset-heavy, capital-intensive.
A 30–35% layoff is not what “conviction” usually looks like. In August 2026, two months before the raise, Even cut ~350 people and explicitly wound down the insurance business it had spent years building. That is consistent with a capital-constrained pivot, not a company compounding on a proven model.
Even is trading an asset-light membership model for 20-year leases and self-built multispecialty hospitals, going from 2 to 7 facilities while its net loss runs ~3× revenue. Its claim of “operationally profitable within a year” is carefully qualified as ex-depreciation — it excludes exactly the capex, depreciation, and lease liabilities that make hospitals so hard to scale. The company has not said publicly how it funds the next five hospitals, when corporate (not single-site) profitability arrives, or what its runway is. The CEO declined to give a profitability timeline.
Three of the round’s most-quoted figures sit above what independent filings and trackers support. None of this is proof of wrongdoing — announced deals and filed deals often differ — but the direction of every gap runs one way.
Announced as a $50M Series B. RoC-filing reporting shows ~₹208 Cr (~$22M), Khosla ~₹145 Cr, and does not name Alpha Wave among filed investors. The “$50M” began life as an ET “in talks” figure and may bundle a separate ~$20M round closed in early 2026.
Even frames ~$300M as triple its mark 18 months earlier. Independent reporting puts the prior valuation near ~$153M — a step-up closer to 2×. The valuation is company-stated and not independently audited.
The company’s “>$120M raised to date” is the outlier: Tracxn shows $72.5M, Entrackr/Inc42 show ~$90M. A prior ~$20M round led by Lachy Groom and Alpha Wave Global sits outside the Series B narrative entirely.
The cautionary comp is Kenko Health — a health-membership/insurance hybrid that raised a ~$11.7M Series A and then entered liquidation in 2024 under IRDAI pressure. Even is now exiting precisely that membership-insurance structure. Whether it is doing so because it chose a better model, or because the hybrid model is structurally fragile in India, is the question the “doubling down” headline never asks.
Seven structural risks the raise does not resolve.
Asset-heavy, 20-year leases, 2→7 hospitals while deeply loss-making. The funding path for the next five facilities is unstated, and “profitable ex-depreciation” excludes the hard costs.
Round size, valuation step-up, and total raised all run ahead of RoC filings and independent trackers. At minimum this signals PR inflation; diligence must use filing data, not the announcement.
The entire value-based-care thesis rests on self-reported stats — sub-1% readmission, 40% shorter stays — with no third-party clinical audit on a young, self-selected membership base.
Three business models in five years plus a 30–35% layoff two months before the raise. The “doubling down” narrative sits uneasily on a track record of reversals.
Owning the hospitals that bill insurers — while touching insurance distribution — invites IRDAI scrutiny and the claim-denial trust problems documented sector-wide in India.
Net loss ~3× revenue and widening; CEO declined to give a profitability timeline; the only profitability claimed is single-site and before depreciation.
Every hospital, member, and outcome figure is Bengaluru-based. There is no evidence yet that the model — or its economics — travels to other Indian cities and payer mixes.
Even is chasing one of the most important problems in Indian healthcare — and may yet build something durable. But the honest read of this raise is a company funding an asset-heavy hospital bet by retreating from two earlier models, while losing roughly 3× its revenue and reporting figures that its own filings don’t support. The $50M-vs-$22M gap, the self-reported outcomes, and the undisclosed path to five more hospitals are the three diligence questions the announcement is built to skip.
Based entirely on publicly available information, including the TechCrunch announcement of October 19, 2026, cross-checked against RoC-filing reporting and independent funding trackers. All outcome and valuation figures are company-stated unless otherwise noted. Dollar/rupee conversions use ~₹95/$.
We build and maintain websites, help businesses of every size put AI to work, and run growth marketing that’s held to the same standard as our research.
